Notice for sacituzumab govitecan (Gilead Sciences Pty Ltd)
Active ingredients
sacituzumab govitecan
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
Therapeutic area
Oncology